RAF 265

Drug Profile

RAF 265

Alternative Names: CHIR-265; RAF265

Latest Information Update: 22 Sep 2015

Price : $50

At a glance

  • Originator Novartis
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Raf kinase inhibitors; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Malignant melanoma; Solid tumours

Most Recent Events

  • 22 Sep 2015 No recent reports on development identified - Phase-I/II for Malignant melanoma (Late-stage disease) in Netherlands, USA, Switzerland (PO)
  • 22 Sep 2015 No recent reports on development identified - Phase-I/II for Solid tumours (Combination therapy, Late-stage disease) in USA (PO)
  • 30 Nov 2013 Novartis completes a phase I/II trial in Malignant melanoma (Late-stage disease) in USA, Netherlands & Switzerland (NCT00304525)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top